10-Q: Applied Therapeutics Reports Second Quarter 2024 Financial Results and Provides Clinical Program Updates

Applied Therapeutics reports a net income of $2.9 million for the second quarter of 2024, a significant turnaround from a net loss of $29.6 million in the same period last year, driven by changes in warrant liabilities.

Summary

• Applied Therapeutics reported a net income of $2.9 million for the three months ended June 30, 2024, compared to a net loss of $29.6 million for the same period in 2023.
• The company's total revenue for the three months ended June 30, 2024, was $0.1 million, primarily from research and development services.
• Research and development expenses decreased to $10.0 million for the three months ended June 30, 2024, from $11.9 million in the same period of 2023.
• General and administrative expenses increased to $10.6 million for the three months ended June 30, 2024, from $5.3 million in the same period of 2023.
• The change in fair value of warrant liabilities resulted in a gain of $22.7 million for the three months ended June 30, 2024, compared to an expense of $12.8 million for the same period in 2023.
• For the six months ended June 30, 2024, the company reported a net loss of $81.0 million, compared to a net loss of $39.7 million for the same period in 2023.
• The company's cash and cash equivalents were $122.2 million as of June 30, 2024.
• The company expects its existing cash and cash equivalents will fund its operating expenses and capital requirements for at least twelve months from the date this report is issued.
• The company received a $10.7 million upfront payment from Advanz Pharma in January 2023 in conjunction with signing a licensing agreement.
• The company has sold an aggregate of 20,615,976 shares of common stock pursuant to the Leerink ATM Agreement with an average sale price of $3.36 per share, resulting in net proceeds of $49.3 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and a strong cash position, the increased net loss and delays in regulatory approvals temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• The company achieved a net income of $2.9 million for the second quarter of 2024, a significant improvement from a net loss of $29.6 million in the same period last year.
• The company's cash position is strong at $122.2 million, expected to fund operations for at least twelve months.
• Positive interim results from the Phase 3 INSPIRE trial for AT-007 in SORD Deficiency were reported.
• The company has a clear regulatory path forward for govorestat for the treatment of SORD Deficiency, with plans to submit an NDA early in the first quarter of 2025.
• The company has successfully raised capital through a private placement and an ATM offering.

Negatives

• The FDA has extended the review period for the NDA for govorestat for the treatment of Classic Galactosemia by three months.
• The company incurred a net loss of $81.0 million for the six months ended June 30, 2024.
• The company's revenue for the six months ended June 30, 2024, was $0.3 million, compared to $10.7 million for the same period in 2023.
• General and administrative expenses increased significantly to $10.6 million for the three months ended June 30, 2024, from $5.3 million in the same period of 2023.

Risks

• The company is subject to risks common to companies in the biotechnology industry, including risks of failure of preclinical studies and clinical trials.
• The company is dependent on key personnel and the protection of proprietary technology.
• The company is subject to compliance with government regulations and reliance on third-party manufacturers.
• The company may face substantial competition and may not achieve market acceptance for its product candidates.
• The company may be adversely affected by product liability lawsuits.
• The company's insurance policies may be inadequate and potentially expose it to unrecoverable risks.
• The company is subject to healthcare laws and regulations, which carry substantial penalties for noncompliance.
• Coverage and adequate reimbursement may not be available for the company's product candidates.
• The company is dependent on third parties to conduct preclinical studies and clinical trials and to produce supplies of its product candidates.
• The company is subject to environmental, health and safety laws and regulations.
• Breaches of the company's license agreements may result in adverse effects to its ability to continue the development and commercialization of its product candidates.
• Insufficient patent protection could allow competitors to develop and commercialize similar products.
• The company may be subject to claims alleging violations of intellectual property rights.
• The company is highly dependent on the services of its current executive officers.
• The company may experience difficulties resulting from the expansion of its organization.
• The company may be subject to security breaches in its information technology systems.
• The company's business may be adversely affected by the coronavirus outbreak.
• The market price of the company's common stock is volatile and has fluctuated substantially.
• The company does not anticipate paying any cash dividends on its capital stock in the foreseeable future.

Future Outlook

The company expects its existing cash and cash equivalents will fund its operating expenses and capital requirements for at least twelve months from the date this report is issued. The company plans to hold a Pre-NDA meeting with the FDA to discuss the NDA submission for govorestat for the treatment of SORD Deficiency in the second half of this year, and expects to submit an NDA early in the first quarter of 2025.

Management Comments

• The FDAs Neurology Division confirmed that the data generated to date was appropriate for a potential NDA submission under the FDAs Accelerated Approval Program.
• The company plans to hold a Pre-NDA meeting with the FDA to discuss the NDA submission in the second half of this year, and expects to submit an NDA early in the first quarter of 2025.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on rare diseases with high unmet medical needs. The company's approach leverages recent technological advances to design improved drugs and employs early use of biomarkers to confirm biological activity. The company is targeting treatments for rare diseases such as Galactosemia and Sorbitol Dehydrogenase (SORD) deficiency.

Comparison to Industry Standards

• The company's approach to drug development, focusing on molecules and pathways with well-known roles in disease processes but previously unsuccessful due to poor efficacy and tolerability, is a common strategy in the biopharmaceutical industry.
• The company's focus on rare diseases is consistent with a trend in the industry to develop treatments for conditions with limited patient populations but high unmet medical needs.
• The company's use of expedited regulatory pathways, such as orphan drug designation and fast track designation, is a common strategy to accelerate the development and approval of drugs for rare diseases.
• The company's reliance on third-party manufacturers and CROs is a common practice in the industry, particularly for smaller companies.
• The company's financial results, including its net loss and cash position, are typical for a clinical-stage biopharmaceutical company that has not yet commercialized any products.
• The company's reliance on licensing agreements for intellectual property is a common practice in the industry, particularly for companies that are developing drugs based on technologies developed by academic institutions.

Corporate Governance

Related Party Transactions

• The company made payments to Alexandria LaunchLabs of approximately $25,000 and $0.1 million during the three and six months ended June 30, 2024, respectively. A member of the company's board of directors is the founder and executive chairman of Alexandria Real Estate Equities, Inc.

Stakeholder Impact

• Shareholders may be impacted by the volatility of the stock price and the company's financial performance.
• Employees may be impacted by changes in the company's operations and growth.
• Patients may benefit from the development of new treatments for rare diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to hold a Pre-NDA meeting with the FDA to discuss the NDA submission for govorestat for the treatment of SORD Deficiency in the second half of this year.
• The company expects to submit an NDA for govorestat for the treatment of SORD Deficiency early in the first quarter of 2025.
• Patients in the INSPIRE study will be offered open-label govorestat treatment and will be followed for additional safety data generation.

Key Dates

Keywords

Galactosemia, SORD Deficiency, Aldose Reductase Inhibitor, AT-007, govorestat, clinical trials, regulatory approval, biopharmaceutical, rare diseases, metabolic diseases